Primevax Immuno-Oncology Inc., of New York, signed an exclusive, worldwide license with the U.S. Army Medical Materials Development Activity authorizing Primevax to use the dengue virus-1 #45AZ5 strain for treatment of cancer. Primevax's therapeutic approach combines the dengue fever virus with dendritic cell therapy. The FDA recently allowed Primevax to begin a trial with their dendritic cells first. In the trial, Primevax will continue treating metastatic melanoma patients after standard-of-care therapies have failed.